Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!

Easy Branches

34/17 Moo 3 Chao fah west Road, Phuket, Thailand, Phuket

Call: 076 367 766

info@easybranches.com

Financial Markets

Shilpa Medicare hits life high on submission of new drug application to USFDA

Shilpa Medicare (SML) climbed 6.12% to Rs 811.25 after the company announced that it has submitted new drug application (NDA) to U.S. Food and Drug Administration (USFDA) for Oxylanthanum Carbonate.

By: business-standard.com

Sep 04 2024
0
8377 Views

Shilpa Medicare hits life high on submission of new drug application to USFDA

Shilpa Medicare hits life high on submission of new drug application to USFDA

Related

Interarch Building invests over Rs 95 crore in manufacturing plant

General Insurance Corporation of India leads losers in 'A' group

Lupin launches Mirabegron Extended-Release Tablets in US

Shilpa Medicare update on its CDMO customer - Unicycive Therapeutics

Lupin hits life high on launching overactive bladder drug in US

Shilpa Medicare hits life high on submission of new drug application to USFDA

HPCL share price rallies 5%, hits record high on falling crude oil prices

Cellecor Gadgets hits 52-week high after announcing to launch electronic gadgets in Sept'24

Sensex, Nifty ends with minor losses; PSU bank shares slides; VIX rallies 3.86%

Chinese markets end lower as services sector activity slows

Hindustan Unilever Ltd gains for third straight session

Metal stocks slide

Interarch Building invests over Rs 95 crore in manufacturing plant